98%
921
2 minutes
20
The Fontan procedure (FP) is typically a semi-elective surgery performed between 2 and 5 years of age to complete staged single ventricle palliation. Optimal timing for the FP, particularly in relation to seasonal infectious burden, remains unclear. We queried the Pediatric Health Information System (PHIS) database for all admissions for viral respiratory infections (VRI) from January 2006 to September 2015 and separately for all admissions with a primary procedure code of FP. The PHIS query generated 2,767,142 admissions for VRI and 6349 admissions for the FP from 45 children's hospitals. Of all FP, 2124 (33.5%) were performed from October through March. The median length of stay after Fontan procedure was 9 days (IQR 7-15). Median length of stay after FP was correlated with VRI burden (correlation coefficient = 0.3, p = 0.03). April through August (weeks 18 through 35) had the lowest VRI admission burden and FP length of stay was significantly shorter during this time (13.6 ± 14.8 days vs 14.9 ± 20.3 days, p = 0.03). The FP is frequently performed during the viral respiratory season. This timing is associated with an increased post-operative length of stay after the FP. For elective FP, ideal timing that avoids the viral respiratory season and minimizes post-operative LOS is April through August.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00246-022-03001-z | DOI Listing |
J Ultrasound Med
September 2025
Evandro Chagas Infectious Diseases National Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
Objectives: The risk of major venous thromboembolism (VTE) among patients with COVID-19 is high but varies with disease severity. Estimate the incidence of lower extremity deep venous thrombosis (DVT) in critically ill hospitalized patients with COVID-19, validate the Wells score for DVT diagnosis, and determine patients' prognosis.
Methods: This was an observational follow-up study in the context of the diagnosis and prognosis of DVT.
Orthop Res Rev
September 2025
Department of Orthopedics and Sports Medicine, Houston Methodist Hospital, Houston, TX, USA.
Objective: The incidence of total shoulder arthroplasty (TSA) in the United States continues to climb as an aging yet active population increases demand for the procedure. Due to promising clinical results out of Europe, improvement in prosthesis design, and wider acceptance of reverse total shoulder arthroplasty (rTSA), this study was designed to evaluate how rTSA and anatomical TSA (aTSA) utilization, patient selection, and length of stay have changed at a single institution.
Methods: This was a retrospective cohort study of patients from one hospital system between 2017 and 2023.
South Afr J Crit Care
May 2025
Department of Paediatrics and Child Health, Faculty of Health Sciences, University of the Free State, Bloemfontein, South Africa.
Background: Procalcitonin (PCT) is used in the diagnosis of sepsis. Its capability as a prognostic marker is unclear. The association between PCT and paediatric intensive care unit (PICU) outcomes has not been investigated in the South African setting.
View Article and Find Full Text PDFFront Pharmacol
August 2025
Department of Anesthesiology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Background: Acetaminophen, a widely used analgesic, has drawn attention for its potential to reduce oxidative stress through inhibiting lipid peroxidation and scavenging free radicals. Emerging evidence indicates that early acetaminophen administration might improve survival outcomes in surgical intensive care unit (SICU) patients. This study aims to explore the relationship between early acetaminophen use and mortality in this patient population.
View Article and Find Full Text PDFArch Cardiovasc Dis
September 2025
Pharmacie, Nantes Université, CHU de Nantes, 44000 Nantes, France; UFR des Sciences Pharmaceutiques et Biologiques, Nantes Université, 44000 Nantes, France. Electronic address:
Background: Patients with acute coronary syndrome requiring coronary artery bypass graft surgery while on ticagrelor face a high risk of perioperative bleeding because of its strong antiplatelet effect. The Cytosorb® haemoadsorbent membrane (CytoSorbents Corporation, Princeton, NJ, USA), which is CE marked for ticagrelor removal, may help to mitigate this risk.
Aim: To evaluate the cost-revenue impact of the use of Cytosorb® membrane over two different time periods in a high-volume French hospital.